Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859129 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
A Phase 1 study of Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT02859129: Completed Phase 1 study of Hypertriglyceridemia, sponsored by AstraZeneca.
NCT02859129 is a Phase 1 study of Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 114 participants, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02859129, a Phase 1 study of Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
Primary Outcome
ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.
Conditions Studied
Interventions
- DRUG rosuvastatin 40 mg tablet
- DRUG Epanova™ QD (2 x 1 g capsules)
- DRUG Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
- DRUG Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Study Locations (1)
New Jersey
- Celerion - Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT02859129 record still lists
NCT02859129 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 4 interventions - of which rosuvastatin 40 mg tablet is the first listed.
NCT02859129 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02859129 about?
NCT02859129 is a clinical study titled "Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)". This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
What is the current status of trial NCT02859129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2013-09. Estimated completion is 2013-11.
What conditions does trial NCT02859129 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT02859129?
The interventions under investigation include: rosuvastatin 40 mg tablet (DRUG), Epanova™ QD (2 x 1 g capsules) (DRUG), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose (DRUG), Multiple (20) oral doses of 2 g Vascepa® every 12 hours (DRUG).
Who is sponsoring clinical trial NCT02859129?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02859129 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02859129's enrollment target sits among peer trials
114 7th of 25 higher than 19 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
COMPLETED · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia